AVITA Medical, Inc.

AVITA Medical is a therapeutic acute wound care company that provides solutions for wound healing. The company's technologies address healing needs from burns, traumatic injuries, and surgical repairs through a portfolio of proprietary and complementary products. These products support wound bed preparation, definitive closure, and recovery. The current commercial portfolio includes RECELL, PermeaDerm, and Cohealyx. RECELL is approved by the United States Food & Drug Administration (FDA) for treating thermal burn wounds and full-thickness skin defects. While RECELL is also approved in the United States for restoring pigmentation of stable depigmented vitiligo lesions, the company has paused further commercial investment in vitiligo. In January 2024, AVITA Medical entered an exclusive multi-year distribution agreement with Stedical Scientific, Inc. to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix, in the U.S. In March 2025, the company also entered a multi-year agreement to manufacture PermeaDerm. In July 2024, AVITA Medical entered an exclusive multi-year development and distribution agreement with Collagen Matrix, LLC d/b/a as Regenity Biosciences, granting exclusive rights to market, sell, and distribute Cohealyx, an AVITA-medical branded collagen-based dermal matrix, in the U.S., with potential expansion into the E.U., Australia, and Japan. Cohealyx was commercially launched in the U.S. on April 1, 2025. AVITA Medical Limited, the former Australian parent company, was founded in December 1992. On October 1, 2019, AVITA Australia began trading its American Depositary Shares on the Nasdaq Capital Market under the symbol "RCEL". In 2020, the Company redomiciled to the U.S.